SCHEMBL16095293

SCHEMBL16095293

Oc1cnn(Cc2ccc(F)cc2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.63
▸ MAPT P10636 4/20 0.63
▸ CREBBP Q92793 1/20 0.50
▸ ALDH1A1 P00352 4/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ HTT P42858 3/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ HSD17B10 Q99714 3/20 0.44
▸ TCF4 P15884 1/20 0.43
▸ CTNNB1 P35222 1/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ SCD5 Q86SK9 1/20 0.41
▸ MET P08581 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7253614 0.81 L3MBTL1 (0.62) CREBBPALDH1A1SMN1; SMN2HSD17B10L3MBTL1
SCHEMBL3085851 0.81 LMNA (0.61) LMNAMAPTCREBBPALDH1A1SMN1; SMN2
SCHEMBL3611556 0.79 MAPT (0.97) LMNAMAPTCREBBPALDH1A1SMN1; SMN2
SCHEMBL3084412 0.79 LMNA (0.63) LMNAMAPTCREBBPALDH1A1SMN1; SMN2
SCHEMBL753052 0.79 HSD17B10 (0.64) LMNAMAPTCREBBPALDH1A1SMN1; SMN2
SCHEMBL18996867 0.78 LMNA (0.58) LMNAMAPTCREBBPALDH1A1SMN1; SMN2
SCHEMBL27375728 0.78 LMNA (0.54) LMNAMAPTCREBBPALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL4500305 0.77 MAPT (1.00) LMNAMAPTCREBBPALDH1A1SMN1; SMN2
SCHEMBL21491759 0.77 LMNA (0.66) LMNAMAPTCREBBPALDH1A1SMN1; SMN2
SCHEMBL15014143 0.77 LMNA (0.61) LMNAMAPTCREBBPALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180319793-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-11-08 — — US disclosed
US-9994562-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-12 — — US disclosed
US-9994562-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-12 — — US disclosed
US-9994562-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-12 — — US disclosed
EP-2970211-B1 HISTONE DEMETHYLASE INHIBITORS QUANTICEL PHARMACEUTICALS INC (US) 2017-07-26 — — EP disclosed
EP-2970211-B1 HISTONE DEMETHYLASE INHIBITORS QUANTICEL PHARMACEUTICALS INC (US) 2017-07-26 — — EP disclosed
US-20160039808-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC 2016-02-11 — — US disclosed
US-20160039808-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC 2016-02-11 — — US disclosed
US-20160039808-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC 2016-02-11 — — US disclosed
EP-2970211-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals Inc (US) 2016-01-20 — — EP disclosed
WO-2014151106-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-09-25 — — WO disclosed
WO-2014151106-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180319793-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C LMNA 2677/4885MAPT 2716/4885CREBBP 375/4885
US-20160039808-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C LMNA 2677/4885MAPT 2716/4885CREBBP 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback